Epitalon
Evidence: CMitochondrial / Cellular Aging
Evidence Snapshot
Regulatory Context
Epitalon is not an FDA-approved drug. FDA scheduled Epitalon-related bulk drug substances for July 2026 Pharmacy Compounding Advisory Committee review and reported insufficient human safety and effectiveness information.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG). It is distinct from Epithalamin, a pineal-gland polypeptide extract. Most direct evidence is cell or animal research, and FDA has identified substantial safety and evidence gaps for compounded use.
Why are researchers interested in it?
Cell studies report effects on telomerase, telomere length, chromatin, and gene-expression markers. These observations do not establish longevity benefits in humans and raise unresolved questions about long-term proliferative and cancer-related risk.
What does the evidence look like?
Evidence grade C/D. Evidence types and limitations are separated below.
Biggest things to know
FDA identified potential immunogenicity concerns from aggregation and peptide-related impurities in compounded products.
Research Takeaway
Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG); it is distinct from Pinealon, which is the tripeptide Glu-Asp-Arg (EDR), and evidence for the two must not be merged.
Evidence boundary: Sequence identity does not establish the marketed composition of any grey-market vial labeled Epitalon.
See all 6 evidence claims →Quick Summary
Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG). It is distinct from Epithalamin, a pineal-gland polypeptide extract. Most direct evidence is cell or animal research, and FDA has identified substantial safety and evidence gaps for compounded use.
Mechanism & Research Overview
Cell studies report effects on telomerase, telomere length, chromatin, and gene-expression markers. These observations do not establish longevity benefits in humans and raise unresolved questions about long-term proliferative and cancer-related risk.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG); it is distinct from Pinealon, which is the tripeptide Glu-Asp-Arg (EDR), and evidence for the two must not be merged.
Does not establish
Evidence boundary: Sequence identity does not establish the marketed composition of any grey-market vial labeled Epitalon.
Sources: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
Supported
Cell-culture studies report telomerase activation and telomere elongation after Epitalon exposure, while animal aging studies do not establish a consistent life-span extension effect.
Does not establish
Evidence boundary: Cellular telomere effects and animal biomarkers do not establish human longevity, anti-aging, or disease-prevention efficacy.
Sources: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells; Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice
Supported
Epitalon is not an FDA-approved drug; FDA has identified substantial safety-information gaps for compounded Epitalon, and a July 2026 advisory-committee recommendation regarding possible 503A-list inclusion does not constitute FDA drug approval.
Does not establish
Evidence boundary: A nonbinding compounding recommendation does not establish safety, effectiveness, marketing approval, or a standardized clinical indication.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA briefing document for Epitalon-related bulk drug substances; FDA summary of safety risks associated with compounded Epitalon
Supported
FDA states that compounded Epitalon may pose immunogenicity and peptide-impurity risks and that it lacks sufficient safety information for proposed compounded routes.
Does not establish
Evidence boundary: Regulatory uncertainty and limited safety information do not prove a specific adverse-event incidence, but they preclude a claim of established safety.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
Limited reports of melatonin-rhythm effects in middle-aged adults do not establish Epitalon as a proven treatment for insomnia, longevity extension, cancer prevention, or generalized anti-aging therapy.
Does not establish
Evidence boundary: Small or historically reported physiological observations are not equivalent to modern pivotal clinical evidence.
Supported
Grey-market or compounded Epitalon products are unapproved and cannot be presumed equivalent to research material; only named-study dosing may appear as Study/Trial Dosing, with no consumer anti-aging or sleep protocol.
Does not establish
Evidence boundary: This does not endorse compounded use or provide a dosing recommendation.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
FDA identified potential immunogenicity concerns from aggregation and peptide-related impurities in compounded products.Safety Consideration
Telomerase activation is a cell-culture finding, not proof of safe lifespan extension; long-term proliferative and carcinogenic risk remains unresolved.Safety Consideration
Human studies are sparse, old, methodologically limited, and often originate from the same research network.Safety Consideration
Epitalon must remain distinct from Epithalamin, a complex animal-tissue extract.
Research Areas Being Studied
Research areas discussed on this page reflect the Mitochondrial / Cellular Aging category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging (2020):
- Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa (2002):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging | 2020 | Middle-aged adults with reduced pineal melatonin function (accelerated pineal-aging / night-shift-work model) | AEDG peptide administration was associated with a 1.7-fold increase in urinary 6-sulfatoxymelatonin excretion and normalization of circadian gene expression (Clock, Csnk1e, Cry2) in middle-aged adults with reduced pineal melatonin function. | Single study from the same research network as most Epitalon literature; not independently replicated. Reports mechanistic/biomarker endpoints (urinary melatonin metabolite, circadian gene expression), not pivotal clinical efficacy data. Studied population is middle-aged adults with an accelerated-pineal-aging/shift-work model, not elderly. Does not demonstrate proven treatment for insomnia, longevity extension, cancer prevention, or generalized anti-aging. | |
| Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa | 2002 | Patients with degenerative retinal lesions plus animal retinal models | The article reports a positive clinical effect in a treated patient series and parallel animal findings, but the available abstract does not provide modern trial-design detail sufficient for confirmatory conclusions. | Older mixed human/animal report with limited methodological detail and uncertain independent replication. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice | 2003 | Female Swiss-derived SHR mice | Epitalon did not change mean life span in this mouse experiment, although selected biomarkers and tumor outcomes were reported. | Single animal study; mixed outcomes and limited generalizability. | |
| Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells | 2003 | Cultured human somatic cells | Epithalon was reported to induce telomerase activity and telomere elongation in cultured human somatic cells. | Cell-culture evidence does not establish human longevity effects or safety. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | 2026 | FDA states that compounded Kisspeptin-10 may pose immunogenicity and peptide-characterization risks and that safety information for proposed routes is absent or limited. The same FDA page separately flags Epitalon and emideltide/DSIP for substantial safety-information gaps in compounded use. | |||
| FDA briefing document for Epitalon-related bulk drug substances | 2026 | FDA Pharmacy Compounding Advisory Committee background review | FDA distinguishes synthetic Epitalon, the tetrapeptide Ala-Glu-Asp-Gly, from Epithalamin, a pineal polypeptide complex. FDA reported insufficient clinical safety and effectiveness information for proposed compounded use and identified theoretical concerns related to telomerase and carcinogenic risk. | The advisory committee meeting was scheduled for July 23–24, 2026; this package predates that meeting and does not state an outcome. | |
| FDA summary of safety risks associated with compounded Epitalon | 2026 | FDA compounding safety-risk summary | FDA states that compounded Epitalon may pose immunogenicity risk from aggregation or peptide-related impurities and that sufficient route-specific human safety information has not been identified. | Official safety context; not a completed clinical trial. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-26.
Follow research updates for Epitalon
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.